Vicore's Phase 2b ASPIRE trial of buloxibutid in IPF passes futility analysis, on track for mid-2027 topline

Vicore Pharma announced its Phase 2b ASPIRE trial of buloxibutid in idiopathic pulmonary fibrosis (IPF) passed the pre-planned futility analysis and remains on track for mid-2027 topline results.

Detected & updated continuously · Source: Nebula